Trump’s trade war could raise Australian medicine costs and limit availability, complicating PBS negotiations and tariff impacts.

In Short

Concerns arise in Australia over a US-Australia trade dispute affecting medicine costs and the Pharmaceutical Benefits Scheme. Potential US tariffs could raise drug prices and impact access, despite the US arguing for higher prices to reflect drug development costs.

Talks of a trade dispute between the US and Australia regarding medicine costs have raised concerns among Australians.

The potential impact on the Pharmaceutical Benefits Scheme (PBS) and tariffs on Australian drugs entering the US raises questions about drug prices and availability.

The PBS offers subsidised medicines, maintaining low out-of-pocket costs for consumers. Drug companies must submit evidence to the Pharmaceutical Benefits Advisory Committee (PBAC), which assesses the cost-effectiveness of drugs.

Donald Trump’s imposition of tariffs could prompt a rise in medicine prices or lead to shortages. Price negotiations occur between the government and drug companies, with consumers paying a fixed co-payment regardless of the drug’s cost to the government.

The US argues the PBS undervalues innovative drugs, seeking higher prices that reflect development costs. However, the PBAC aims to keep prices low, benefiting consumers.

Tariffs on Australian pharmaceuticals exported to the US could hike prices and reduce demand for Australian-made drugs, although most medicines in Australia are sourced overseas.

Even if Australia retaliated with tariffs on US pharmaceuticals, it would likely harm access to innovative drugs and lead to increased negotiation restrictions.

While the trade negotiations’ outcome remains uncertain, it is unlikely the US can significantly influence Australian pharmaceutical pricing, especially with anticipated reductions in consumer drug costs.